We want to hear from you. Submit suggestions for new AGA guideline topics by April 8, 2017.
AGA develops clinical practice guidelines using the most up-to-date research to help you practice evidence-based medicine. Clinical practice guidelines are critical to reducing physician variation and providing high-quality patient care. We want your input for developing the next set of these critical guidelines.
By completing this online form, you may submit recommendations for guideline topics that will be developed within the next two years. You can submit more than one guideline topic by filling out the form multiple times. The deadline is Saturday, April 8, 2017, at 5 p.m. ET.
The AGA’s clinical guidelines are evidence-based recommendations to help guide your clinical practice decisions based on rigorous systematic reviews of the medical literature.
AGA utilizes the GRADE system (Grades of Recommendation Assessment, Development and Evaluation). Learn about GRADE. Our guidelines are regularly reviewed for accuracy. Learn about the update process. AGA endorses guidelines that meet the IOM's rigorous criteria for evidence-based clinical recommendations. Endorsement criteria and methods.
AGA Pocket Guides
Official AGA Institute quick-reference tools provide healthcare providers and students with instant access to current guidelines and clinical care pathways in a clear, concise format. AGA Institute pocket guides are available in print and digital form.
AGA members: Purchase print copies or download digital versions for free.
Non-members: Access print and digital copies available for purchase.
Click the arrow on the right of each category to view related guidelines, clinical support tools, and other evidence-based practice resources.
In the U.S., colorectal cancer (CRC) is the third most common cancer diagnosed among men and women and the second leading cause of death from cancer. CRC largely can be prevented by the detection and removal of adenomatous polyps. AGA offers a broad portfolio of guidelines, decision support tools and standards to support high-quality patient care.
Screening for Early Detection
Colorectal Cancer Screening and Surveillance for Early Detection
Colonoscopy After Cancer Resection
Colonoscopy Surveillance After Cancer Resection
Colonoscopy After Polypectomy
Colonoscopy Surveillance After Screening and Polypectomy
Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer
Optimizing Adequacy of Bowel Cleansing for Colonoscopy: Recommendations From the US Multi-Society Task Force on Colorectal Cancer
The two inflammatory bowel diseases (IBD) are Crohn’s disease and ulcerative colitis (UC). Most care for these chronic diseases occurs in the outpatient setting, with hospitalizations reserved for complications that might require surgery. AGA offers a guideline on drug therapy and decision support tools for patient management.
Guidelines for the Identification, Assessment and Initial Medical Treatment in Crohn’s Disease
Drug Therapy for Crohn’s
Inflammatory Crohn’s Disease: Thiopurines, Methotrexate and Anti-TNF-α Biologic Drugs for Induction and Maintenance of Remission
Identification, Assessment and Intiial Medical Treatment of Ulcerative Colitis
Medical Management of Microscopic Colitis
Therapeutic Drug Monitoring in IBD
Expected Summer 2017
Two of the most common esophageal diseases seen by gastroenterologists are Barrett’s esophagus and GERD. AGA resources focus on major clinical issues encountered by physicians who treat patients with Barrett's esophagus and the general issues related to managing GERD.
Gastroesophageal Reflux Disease (GERD)
Gastroesophageal Reflux Disease (GERD)
AGA’s liver disease resources include guidelines and decision tools for hepatitis C screening and evaluation, how to handle hepatitis B reactivation during immunosuppressive therapy and managing NAFLD patients.
Hepatitis C Screening and Evaluation
Hepatitis B Reactivation
Hepatitis B Reactivation During Immunosuppressive Drug Therapy
Acute pancreatitis is a disease of increasing annual incidence and one that produces significant morbidity and mortality and consumes enormous health care resources. AGA provides guidelines to guide clinicians in the management of patients with both mild and severe acute pancreatitis.
Initial Management of Acute Pancreatitis
Expected Early 2018
Irritable Bowel Syndrome
IBS is the most common diagnosis in clinical gastroenterology. It is estimated that approximately 10 to 15 percent of the general adult population is affected. AGA offers recommendations about pharmacological therapy for IBS-C (constipation) and IBS-D (diarrhea).
Functional GI Disorders
Functional GI disorders affect patient quality of life. AGA offers a growing portfolio of resources to help care for patients with these disorders.
Evaluation of Chronic Diarrhea
Expected early 2018
Clinical practice guidelines are developed under the aegis of the AGA Institute Clinical Guideline Committee and provide preferred approaches to specific medical problems or issues.
|Guideline Topic||Expected Publication Date|
|Role of Elastography in the Evaluation of Liver Fibrosis||Summer 2017|
|Therapeutic Monitoring in Inflammatory Bowel Disease||Summer 2017|
|Initial Management of Acute Pancreatitis||Early 2018|
|Evaluation of Chronic Diarrhea||Early 2018|
|Update on the 2014 Guideline on the Pharmacological Management of Irritable Bowel Syndrome||Early 2018|
|Management of Opioid-Induced Constipation||Early 2018|
|GI Cancer Survillance in Gastric Intestinal Metaplasia||Spring 2018|
|Management of Mild to Moderate Ulcerative Colitis||Spring 2018|
|Management of Eosinophilic Esophagitis||Spring 2018|